KLARA CZOBOR: Can you talk about what TXL is and how it addresses the unmet need in the treatment of hepatitis B? JAMES SAPIRSTEIN: Well, TXL is a lipid conjugate of a drug that’s already available, a lipid conjugate of tenofovir. And basically, right now, it’s very early stage for hepatitis B. We know that […]